
MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitiv... MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation for the treatment of adult patients with anxiety and cognitive decline typically associated with early-stage dementia. It is developing MIRA1a, a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting the cannabinoid type 1 and type 2 receptors. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Baltimore, Maryland. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.04 | -3.22580645161 | 1.24 | 1.34 | 1.16 | 260358 | 1.25442858 | CS |
4 | -0.05 | -4 | 1.25 | 1.44 | 1.16 | 193752 | 1.30026953 | CS |
12 | 0.15 | 14.2857142857 | 1.05 | 1.53 | 0.73 | 1291924 | 1.0953218 | CS |
26 | 0.08 | 7.14285714286 | 1.12 | 1.53 | 0.73 | 790227 | 1.11640652 | CS |
52 | 0.4829 | 67.3406777297 | 0.7171 | 5.01 | 0.51 | 2189022 | 2.70272864 | CS |
156 | -5.8 | -82.8571428571 | 7 | 7.9799 | 0.51 | 1304558 | 2.6230428 | CS |
260 | -5.8 | -82.8571428571 | 7 | 7.9799 | 0.51 | 1304558 | 2.6230428 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.